RECRUITING

Biology of Young Lung Cancer Study: The YOUNG LUNG Study

Talk to us

Conditions

Non Small Cell Lung CancerSmall Cell Lung CarcinomaNUT CarcinomaGeneticsGenomicsYoung lung cancer

Quick Navigation

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

The purpose of this research study is to learn more about lung cancer (NSCLC or SCLC) diagnosed in adults at ages 45 or younger.

Official Title

Biology of Young Lung Cancer Study: The YOUNG LUNG Study

Quick Facts

Study Start:2023-01-01
Study Completion:2027-08-01
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT05265429

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:15 Years to 45 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:No
Standard Ages:CHILD, ADULT
Inclusion CriteriaExclusion Criteria
  1. * Age 45 and under at lung cancer diagnosis
  2. * Pathologically confirmed bronchogenic lung carcinoma (NSCLC or SCLC of any stage) at any treatment time point
  3. * Provision of written informed consent
  4. * Willingness to undergo no more than two (2) peripheral blood draws in a four (4) week period, with no more than 50 ml peripheral blood collected over eight (8) weeks
  5. * Individuals under age 18 are eligible for study if they meet defined criteria; in addition, consent for participation must be given by a legal guardian or parent
  1. * Individuals who decline to sign consent
  2. * Individuals who are unable to give consent or assent and are without a designated healthcare proxy
  3. * Compromise of patient diagnosis or staging if tissue is used for research

Contacts and Locations

Study Contact

Pasi A Janne, MD, PhD
CONTACT
617-632-6036
Pasi_Janne@dfci.harvard.edu

Principal Investigator

Pasi A Janne, MD, PhD
PRINCIPAL_INVESTIGATOR
Dana-Farber Cancer Institute

Study Locations (Sites)

Massachusetts General Hospital
Boston, Massachusetts, 02114
United States
Beth Israel Deaconess Medical Center
Boston, Massachusetts, 02115
United States
Brigham and Women's Hospital
Boston, Massachusetts, 02115
United States
Dana-Farber Cancer Institute
Boston, Massachusetts, 02115
United States

Collaborators and Investigators

Sponsor: Dana-Farber Cancer Institute

  • Pasi A Janne, MD, PhD, PRINCIPAL_INVESTIGATOR, Dana-Farber Cancer Institute

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2023-01-01
Study Completion Date2027-08-01

Study Record Updates

Study Start Date2023-01-01
Study Completion Date2027-08-01

Terms related to this study

Keywords Provided by Researchers

  • Non Small Cell Lung Cancer
  • Small Cell Lung Carcinoma
  • Genetics
  • Genomics
  • Young lung cancer

Additional Relevant MeSH Terms

  • Non Small Cell Lung Cancer
  • Small Cell Lung Carcinoma
  • NUT Carcinoma